Val-Cit-Exatecan (TFA)

• UNSPSC Description:

  Val-Cit-Exatecan TFA is an agent-linker conjugate for ADC. Val-Cit-Exatecan TFA is composed of a DNA topoisomerase I Exatecan (HY-13631) and a cathepsin cleavable ADC linker[1].

• Target Antigen:

  Drug-Linker Conjugates for ADC

• Type:

  Reference compound

• Related Pathways:

  Antibody-drug Conjugate/ADC Related

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/val-cit-exatecan-tfa.html

• Smiles:

  CC(C)[C@H](N)C(N[C@@H](CCCNC(N)=O)C(NCOCC(N[C@@H]1C2=C3C(C(N4C3)=CC([C@](O)(C(OC5)=O)CC)=C5C4=O)=NC6=CC(F)=C(C)C(CC1)=C62)=O)=O)=O.O=C(O)C(F)(F)F

• Molecular Weight:

  892.85

• References & Citations:

  [1]Thomas A, et al. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 2016 Jun;17(6):e254-e262

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported